Strategy
MSTR
Coinbase
COIN
Alphabet-A
GOOGL
Alphabet-C
GOOG
Meritage Homes
MTH
US Stock MarketDetailed Quotes
ZBIO Zenas BioPharma
- 6.930
- +0.290+4.37%
Close Mar 4 16:00 ET
- 6.930
- 0.0000.00%
Post 20:01 ET
289.61MMarket Cap-2.24P/E (TTM)
6.960High6.130Low113.32KVolume6.520Open6.640Pre Close767.20KTurnover0.96%Turnover RatioLossP/E (Static)41.79MShares26.25152wk High0.81P/B81.50MFloat Cap5.83052wk Low--Dividend TTM11.76MShs Float26.251Historical High--Div YieldTTM12.50%Amplitude5.830Historical Low6.769Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Zenas BioPharma Stock Forum
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
Wednesday, 5th February at 7:05 am
- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function-
-Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025-
-Topline results from pivotal Phase 3 Tr...
No comment yet